Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling.

The estrogen receptor (ER) drives growth in most breast cancers. Endocrine therapy reduces recurrence, however around 30% of cancers relapse. Many recurrences occur years later, with slowly proliferating, hard-to-treat disease. To study this, we generate slow-growing resistant cells that form small primary tumours but readily metastasise. Single-cell RNA sequencing (scRNAseq) reveals that endocrine therapy reprograms these cells, notably upregulating the Rac1 signalling component P-Rex1. We find in clinical cohorts that P-Rex1 is high in ER+ breast cancer, including in late recurrent disease. Intravital imaging demonstrates that Rac1 signalling is active in ER+ cells following endocrine therapy. Targeting the Rac1 pathway with small molecule inhibitors (NSC23766, R-ketorolac) reduces survival and motility in resistant cells, inhibits in vivo Rac1 activity, and reduces tumour burden when combined with tamoxifen in a drug-refractory patient derived xenograft model. This work identifies the P-Rex1/Rac1 axis as a potential therapeutic target for late recurring ER+ breast cancer.

Authors

Institutions

Publication Details

Journal
Open Access CRIS of the University of Bern
Published
2026-05-11
DOI
https://doi.org/10.48620/97671
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling.

Hannah Williams, Janett Stoehr, Max Nobis, Sarah Alexandrou et al.
Open Access CRIS of the University of Bern
Cancer Cells and Metastasis
article

Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling.

Hannah Williams, Janett Stoehr, Max Nobis, Sarah Alexandrou, Kate Harvey, David Gallego‐Ortega, Yolanda Colino‐Sanguino, Alexander Swarbrick, Fátima Valdés‐Mora, Nenad Bartoniček, Christina A. Mitchell, Ghazal Sultani, Paul Timpson, Lisa M. Ooms, Emily I. Jones, Leila Eshraghi, Margaret C. Cummings, Sunny Wu, Christine Lee, Brian Gloss, Maryam Hasha Simad, Rob Salomon, Victoria Lee, C Elizabeth Caldon, Amy E McCart Reed, Samantha R Oakes, Daniel L Roden, Kristine J Fernandez, Sunil R Lakhani, Ewan K A Millar, Elgene Lim, Thomas R Cox, Ellie T Y Mok, Jamie R Kutasovic, Peter T Simpson
article en

Abstract

The estrogen receptor (ER) drives growth in most breast cancers. Endocrine therapy reduces recurrence, however around 30% of cancers relapse. Many recurrences occur years later, with slowly proliferating, hard-to-treat disease. To study this, we generate slow-growing resistant cells that form small primary tumours but readily metastasise. Single-cell RNA sequencing (scRNAseq) reveals that endocrine therapy reprograms these cells, notably upregulating the Rac1 signalling component P-Rex1. We find in clinical cohorts that P-Rex1 is high in ER+ breast cancer, including in late recurrent disease. Intravital imaging demonstrates that Rac1 signalling is active in ER+ cells following endocrine therapy. Targeting the Rac1 pathway with small molecule inhibitors (NSC23766, R-ketorolac) reduces survival and motility in resistant cells, inhibits in vivo Rac1 activity, and reduces tumour burden when combined with tamoxifen in a drug-refractory patient derived xenograft model. This work identifies the P-Rex1/Rac1 axis as a potential therapeutic target for late recurring ER+ breast cancer.

Open Access CRIS of the University of Bern
Tissue Genetics (United States) (US)
Good health and well-being
Openalex Percentile: Top 5%
Cancer Cells and Metastasis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.